This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By simulating trials at scale, QuantHealth’s platform can lower risks, expedite, and optimize drugdevelopment. QuantHealth is already working with several global pharmaceutical companies to use its product in clinical trial design and development. Petra Jantzer, Ph.D., Originally announced January 8th, 2024
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drugdevelopment processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.
He sees three major developments: healthcare will become a digital-first system; decentralization will become a major theme for health and lifesciences organizations; and video will be part of every healthcare experience. Healthcare IT News interviewed Emerson to have him expand upon his predictions for the year.
The development and manufacturing process for these important new drugs is very different from traditional medicines. This article focuses on the technology that ensures quality in the process, and is based on a conversation with Graziella Piras, PhD, LifeScience Business Development Director at 908 Devices.
PicnicHealth , a patient-centered healthcare evidence generation company, today announced the acquisition of AllStripes , a platform dedicated to generating evidence about the rare disease community. The focus of the solutions will be making clinical research and registry development more effective and efficient.
an oncology real-world data and analytics company, announced its latest financing by an investment fund managed by Deerfield Management , a healthcare investment firm. Deerfield invests across the lifescience, medical device, diagnostic, digital health, and health service industries at every stage of evolution. COTA, Inc. ,
We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. Jane Reed, Director of LifeSciences at Linguamatics, an IQVIA company Pharmaceutical developers have always prioritized drug safety.
We are particularly excited about the ability of these tools to drive more efficient and faster drugdevelopment processes in the biopharma industry.” “The About Novalis LifeSciences LLC Novalis LifeSciences is the investment arm of Novalis Capital Partners, a boutique investment and advisory firm for the LifeScience industry.
As precision medicine becomes more nuanced and complex, biopharmaceutical companies are increasingly turning to AI to enhance the utility, performance, and scalability of computational pathology analyses for drugdevelopment and diagnostics. Aignostics is funded by leading investors and has operations in Berlin and New York.
.” Prognos Health’s platform is used by over 70 lifesciences customers to accelerate the development of new drugs, improve the safety and efficacy of existing drugs, and identify new patient populations that may benefit from specific treatments.
We reached out to our incredible Healthcare IT Today Community to get their insights on what will happen in the coming year and boy did they deliver. Alyssa Farrell, Director, Global Health Care & LifeSciences Industry Marketing at SAS Targeted AI applications drive expanded AI usage.
Blockchain technology’s potential impact on the lifesciences industry (drugdevelopment, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain.
Its software can significantly accelerate data analysis and healthcare research. Cornerstone’s founders incubated the company in partnership with Initiate Studios, a new venture studio that co-creates companies at the intersection of healthcare, lifesciences and technology.
Mountain Group Partners is an investor dedicated to investing in and actively guiding transformational businesses in the Technology, Animal Health, and LifeSciences sectors. Technology investments focus on business and healthcare technology, targeting those ideas with quantifiable development risk and a rapid path to market.
The WHO and the India G20 presidency emphasised its importance by launching ‘The Global Initiative of Digital Health’ (GIDH) in August, proclaiming: “Digital health is a proven accelerator to advance health outcomes and achieve Universal Health Coverage and health-related Sustainable Development Goals.”
We reached out to our incredible Healthcare IT Today Community to get their insights on what will happen in the coming year and boy did they deliver. Drug discovery and development will see the most dramatic impact, with AI-powered processes reducing development timelines from 10-12 years to as little as a quarter of that time.
This platform is designed to meet the demands of health systems and lifescience companies working to solve increasingly global, diverse, and data-intensive healthcare problems. Atropos’ unique global offerings help lifescience leaders overcome this challenge.
We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. Jesse Cugliotta, Global Industry GTM Lead, Healthcare & LifeSciences at Snowflake. Check out our community’s pharma predictions.
We asked the Healthcare IT Today community to submit their predictions and we received a wide ranging set of responses that we grouped into a number of themes. But what most healthcare professionals don’t realize is that AI can do so much more than respond to patient messages.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content